tetano
Editor, Senior Moderator
Int J Emerg Med
. 2021 Nov 6;14(1):68.
doi: 10.1186/s12245-021-00393-2.
Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
Vaibhav Rastogi[SUP] 1 2 [/SUP], Ranjit Banwait[SUP] 3 [/SUP], Devina Singh[SUP] 3 [/SUP], Hale Toklu[SUP] 1 3 [/SUP], Lexie Finer[SUP] 1 [/SUP], Dipendra Parajuli[SUP] 4 [/SUP], Latha Ganti[SUP] 5 6 7 [/SUP]
Affiliations
Abstract
Background: (1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort.
Results: Forty-five thousand three hundred sixty patients were included in the analysis, 62.82% of which had either hepatic or pancreatic injury. There was a significant upward trend in transaminases, alkaline phosphatase, prothrombin time, bilirubin, lactate dehydrogenase, and lipase and a downward trend in albumin with an increase in disease severity. COVID-19-positive patients with hepato-pancreatic injury have a significantly higher mortality (OR 3.39, 95%CI 3.15-3.65) after controlling for the differences in age, sex, race/ethnicity, liver cirrhosis, and medication exposures. They also have increased disease severity (OR 2.7, 95%CI 2.5-2.9 critical vs mild/moderate; OR 1.4, 95% CI 1.3-1.5 severe vs mild/moderate) and longer hospital length of stay (2 days).
Conclusion: COVID-19 can cause liver injury. Mortality, disease severity, and hospital length of stay are increased in COVID-19 patients with hepatopancreatic injury.
Keywords: Liver; Mortality; Pancreas; SARS-CoV2.
. 2021 Nov 6;14(1):68.
doi: 10.1186/s12245-021-00393-2.
Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
Vaibhav Rastogi[SUP] 1 2 [/SUP], Ranjit Banwait[SUP] 3 [/SUP], Devina Singh[SUP] 3 [/SUP], Hale Toklu[SUP] 1 3 [/SUP], Lexie Finer[SUP] 1 [/SUP], Dipendra Parajuli[SUP] 4 [/SUP], Latha Ganti[SUP] 5 6 7 [/SUP]
Affiliations
- PMID: 34742236
- DOI: 10.1186/s12245-021-00393-2
Abstract
Background: (1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort.
Results: Forty-five thousand three hundred sixty patients were included in the analysis, 62.82% of which had either hepatic or pancreatic injury. There was a significant upward trend in transaminases, alkaline phosphatase, prothrombin time, bilirubin, lactate dehydrogenase, and lipase and a downward trend in albumin with an increase in disease severity. COVID-19-positive patients with hepato-pancreatic injury have a significantly higher mortality (OR 3.39, 95%CI 3.15-3.65) after controlling for the differences in age, sex, race/ethnicity, liver cirrhosis, and medication exposures. They also have increased disease severity (OR 2.7, 95%CI 2.5-2.9 critical vs mild/moderate; OR 1.4, 95% CI 1.3-1.5 severe vs mild/moderate) and longer hospital length of stay (2 days).
Conclusion: COVID-19 can cause liver injury. Mortality, disease severity, and hospital length of stay are increased in COVID-19 patients with hepatopancreatic injury.
Keywords: Liver; Mortality; Pancreas; SARS-CoV2.